-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
2022 is destined to be an extraordinary year, the continuous rush of the new crown epidemic has accelerated the differentiation of the global health field, and industry giants have opened a rush mode
.
Among the top ten mergers and acquisitions in the global health field in 2022, Pfizer has carried out three mergers and acquisitions with strong financial resources, Amgen and United Health have each carried out two mergers and acquisitions, and Johnson & Johnson, CSL, Bristol-Myers Squibb have each carried out one merger
.
TOP 1
TOP 1Amgen Buys $27.
8 Billion to Horizon Therapeutics (Rare Disease, Autoimmune Disease)
8 Billion to Horizon Therapeutics (Rare Disease, Autoimmune Disease)
On December 12, according to Bloomberg, Amgen will acquire biotech company Horizon for $116.
50 per share
Therapeutics, which will total $27.
8 billion, is about to become Amgen's largest acquisition in history
.
Founded in 2008 and headquartered in Dublin, Ireland, Horizon develops drugs for rare and autoimmune diseases, and its current mainstay is Tepezza, a monoclonal antibody targeting IGF-1R, which was first approved by the FDA in January 2020
.
In addition, the company also has a range of drugs
such as Krystexxa for chronic gout, Ravicti for the treatment of urea cycle disorders in rare genetic diseases, and Uplizna for the treatment of optic nerve and spinal cord inflammation.
TOP 2
TOP 2Johnson & Johnson Spends $16.
6 Billion to Acquire Abiomed (Heart Pump Manufacturing)
6 Billion to Acquire Abiomed (Heart Pump Manufacturing)
On November 1, global medical device giant Johnson & Johnson announced the acquisition of artificial heart maker Abiomed for $16.
6 billion to consolidate its cardiovascular device business line
.
In 2022, Abiomed has not had a good time, and its share price has fallen sharply by nearly 30%.
Johnson & Johnson took the opportunity to take advantage of Abiomed's leading position in cardiac circulatory support technology, which can help the company expand its cardiovascular business and compete with Medtronic
.
The transaction is also the first major acquisition since Johnson & Johnson divested its consumer health business last year, and under the agreement, all shareholders will also receive up to $35 in cash proceeds
if Abiomed can meet established commercial and clinical milestones.
TOP 3
TOP 3CSL spent a year acquiring Vifor Pharma for $11.
7 billion (iron deficiency anemia, kidney disease)
7 billion (iron deficiency anemia, kidney disease)
As of December 14, 2021, CSL announced Vifor
Pharma's acquisition plan came under strict government regulation after nearly a year of tug-of-war
.
On August 9, 2022, CSL finalized its acquisition of Vifor Pharma, which CSL will acquire
97% shares
.
It is widely believed that this transaction will give CSL access to Vifor's kidney disease and iron deficiency treatment products, which currently relies heavily on the immunoglobulin portfolio, but CSL's performance has continued to be under pressure
for several years due to plasma collection barriers caused by the new crown epidemic.
Paul CEO of CSL
Perreault highly appreciates the acquisition, arguing that Vifor's addition to CSL can add short-term value while embarking on a long-term sustainable growth path, and that Vifor brings an excellent management team and a high-value, complementary product portfolio to CSL, which will establish the new company's market leadership
in nephrology and iron deficiency treatment.
TOP 4
TOP 4Pfizer buys Biohaven Pharmaceuticals for $11.
6 billion (migraine)
6 billion (migraine)
On May 10, Pfizer officially announced that it will acquire Biohaven, a leader in the migraine field, and the transaction is expected to be completed
in 2023.
Under the terms of the agreement, Pfizer will acquire all outstanding shares of Biohaven for $148.
5 per share in cash, for a total transaction of $11.
6 billion.
Upon completion of the acquisition, Pfizer will acquire Biohaven's CGRP program, including rimegepant, zavegepant, and five preclinical programs
.
Biohaven relied on excellent vision and capitalization operations to pocket the innovations of multiple laboratories and pharmaceutical companies, and eventually gave birth to two "blockbusters" in the field of migraine - rimegepant and zavegepant
.
Interestingly, both drugs were "cut off" from BMS, and in 2016, Biohaven completed the acquisition
of both drugs for only $350 million.
TOP 5
TOP 5United Health acquires Change Healthcare for $7.
8 billion
8 billion
On September 20, United Health Group acquired Change, a medical information company, for $7.
8 billion
The Healthcare deal was approved by the court after it was subject to antitrust litigation by the U.
S.
Department of Justice on the grounds that UnitedHealth would have access to large amounts of healthcare data
once the merger is completed.
Change
Founded in 2006, Healthcare is the leading independent healthcare technology company in the United States, providing data and analytics-driven solutions to improve clinical, financial, and patient engagement outcomes
in the U.
S.
healthcare system.
After completing the acquisition, Change
Healthcare will merge with the Optum segment to process drug claims and provide care and technical support services
.
TOP 6
TOP 6Pfizer acquires Arena Pharmaceuticals for $6.
7 billion (gastroenterology, dermatology, cardiology)
7 billion (gastroenterology, dermatology, cardiology)
On March 19, Pfizer officially completed the acquisition of Arena for a total of $6.
7 billion
.
Arena's common stock was delisted on the NASDAQ on March 11, and the company's pipeline products are focused on gastroenterology, dermatology and cardiology
.
Among them, the most exciting thing for Pfizer is a highly selective oral sphingosine 1-phosphate (SIP) - etrasimod, which has shown broad application prospects
in the treatment of Crohn's disease.
The drug may also be used in a variety of immune-mediated inflammatory diseases, including ulcerative colitis, eosinophilic esophagitis, and atopic dermatitis and alopecia areata
.
The acquisition will further strengthen Pfizer's portfolio of drug candidates in gastroenterology, dermatology and cardiology, providing differentiated treatment options
for patients.
TOP 7
TOP 7Pfizer acquires Global Blood Therapeutics for $5.
4 billion
4 billion
On August 8, Pfizer announced that it had reached an agreement with Global Blood Therapeutics (GBT) to acquire all outstanding shares of GBT under the terms of the transaction, including debt and net cash from the acquisition, for a total value of approximately $5.
4 billion.
GBT has a rich track record in the treatment of sickle cell anemia (SCD), a lifelong, devastating inherited blood disorder characterized by hemolytic anemia, acute pain crises and progressive terminal organ damage that plagues millions of people worldwide, mainly in Africa, the Middle East and South Asia
.
GBT is developing GBT021601 (GBT601), an oral next-generation inhibitor of sickle hemoglobin (Hbs) polymerization, which has the potential to be one of the best drugs to improve hemolysis and vaso-occlusive crisis (VOC), VOC is caused by sickle-shaped red blood cells irritating the lining of blood vessels and causing an inflammatory response, resulting in vascular occlusion, tissue ischemia and pain; GBT's other monoclonal antibody against P-selectin, inclacumab, is also a rising star
against VOCs.
TOP 8
TOP 8UnitedHealth's $5.
4 billion acquisition of LHC Group (Home Healthcare)
4 billion acquisition of LHC Group (Home Healthcare)
On March 29, UnitedHealth Group announced that it would acquire LHC
, a home healthcare company, for $5.
4 billion in cash.
United Health Group has expanded its home health services in recent years, and the deal aims to include seniors with chronic diseases and provide them with personalized medical services
.
LHC Group, which employs 30,000 people, including frontline healthcare staff, administrative and support staff, can provide more than 12 million home interventions per year, following the completion of the acquisition
The Group's management will be integrated into Optum to continue to lead the team
.
TOP 9
TOP 9Bristol-Myers Squibb acquires Turning Point Therapeutics for $4.
1 billion
1 billion
On June 3, BMS announced it would acquire Turning Point Therapeutics, under which BMS will acquire Turning for $76 per share
Point, worth $4.
1 billion
.
Turning Point
Therapeutics is a clinical-stage precision oncology company with a portfolio of investigational drugs designed to target the most common mutations
associated with cancer.
The company's most significant assets are the next generation of potential blockbuster tyrosine kinase inhibitors (TKIs), non-small cell lung cancer (NSCLC), and drugs
targeting other advanced solid tumors, ROS1 and NTRK.
Turning Point
Therapeutics' product line includes Repotrectinib, TPX-0022, TPX-0046, and the next-generation ALK inhibitor TPS-0131
。 Repotrectinib has been granted breakthrough therapy for first-line treatment of ROS1-positive metastatic NSCLC who have not received ROS1 inhibitors, breakthrough therapy
for patients with advanced solid tumors with NTRK gene fusion, and ROS1-positive metastatic NSCLC who have previously received ROS1 inhibitors and have not received platinum-containing chemotherapy for the indications of ROS1-positive NSCLC and NTRK fusion-positive solid tumors 。 It is expected that in the second half of 2023, Repotrectinib may be approved in the United States, with peak sales likely to reach $1-1.
5 billion
.
TOP 10
TOP 10Amgen acquires Chemo Centrix for $3.
7 billion (autoimmune disease)
7 billion (autoimmune disease)
On August 4, Amgen and Chemo Centrix jointly announced that the two companies have reached an acquisition intention, and Amgen will acquire Chemo Centrix
for $3.
7 billion.
Amgen's acquisition of Tavneos will cement its decades-long leadership in inflammation and nephrology as an orally administered selective complement 5a (C5a), which was approved by the FDA in October 2021 as an adjunct therapy in adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis, particularly for the treatment
of granulomatosis with polyangiitis and microscopic polyangiitis.
In addition to Tavneos, ChemoCentryx also has
3 early-stage drug candidates, including those targeting chemokine receptors in other inflammatory diseases and a potentially anti-cancer oral checkpoint inhibitor
.
The magnificent year of 2022 has ended, the journey of 2023 has begun, and it will be interesting to see who can seize the opportunity in the current booming global health field
.
In the near future, Medical Geography will continue to publish annual inventory articles, so that we can witness the history and explore the future
